Baseline clinical characteristics of antiphospholipid carriers, prophylaxis and the thrombosis rate in the study subjects
| Clinical characteristics | Prevalence | Thrombotic events | |
|---|---|---|---|
| No | Yes | ||
| Systemic autoimmune diseases | 177/258 (68.6%) | 167/244 (68.4%) | 10/14 (71.4%) |
| Systemic lupus erythematosus | 70/258 (27.1%) | 66/244 (27.0%) | 4/14 (28.6%) |
| Others* | 107/258 (41.5%) | 101/244 (41.4%) | 6/14 (42.9%) |
| No systemic autoimmune diseases | 81/258 (31.4%) | 77/244 (31.6%) | 4/14 (28.6%) |
| Women who were or had been pregnant | 144/223 (64.6%) | 140/213 (65.7%) | 4/10 (40.0%) |
| Obstetric antiphospholipid syndrome (APS)† | 49/144 (34.0%) | 46/140 (32.9%) | 3/4 (75.0%) |
| No obstetric APS | 95/144 (66.0%) | 94/140 (67.1%) | 1/4 (25.0%) |
| Thrombophylic risk factors | |||
| Pregnancy/puerperium | 26/155 (16.8%)‡ | 24/147 (16.3%) | 2/8 (25.0%) |
| Smoking | 60/258 (23.3%) | 58/244 (23.8%) | 2/14 (14.3%) |
| Hypertension (systolic >140, diastolic >90) | 47/258 (18.2%) | 41/244 (16.8%) | 6/14 (42.9%)§ |
| Hypercholesterolaemia (>240 mg/dl) | 22/258 (8.5%) | 21/244 (8.6%) | 1/14 (7.1%) |
| BMI >85th percentile | 15/258 (5.8%) | 15/244 (6.1%) | 0/14 (0.0%) |
| Pill/hormone replacement therapy | 12/223 (5.4%) | 12/213 (5.6%) | 0/10 (0.0%) |
| Diabetes mellitus | 5/258 (1.9%) | 5/244 (2.0%) | 0/14 (0.0%) |
| Prophylaxis | |||
| Long-term¶ | 140/258 (54.3%) | 132/244 (54.1%) | 8/14 (57.1%) |
| Only during risk situations** | 68/98 (69.4%) | 66/93 (71.0%) | 2/5 (40.0%) |
↵* 50 undifferentiated connective tissue disease, 32 autoimmune thyroiditis, 9 rheumatoid arthritis, 7 autoimmune thrombocytopenia, 7 vasculitis, 6 systemic sclerosis, 6 Sjögren's syndrome and 15 other types of autoimmune diseases (36 patients had contemporaneously more than one autoimmune diseases).
↵† 32 fetal losses (type a), 11 premature births (type b) and 13 early abortions (type c) (7 of these women had contemporaneously more than one type of pregnancy morbidity).
↵‡ Women of childbearing age.
↵§ Statistically significant (p<0.05).
↵¶ 138 with low-dose aspirin (LDA) and 2 with warfarin.
↵** 15 surgery/immobilisation (14 with low molecular weight heparin, 1 with warfarin), 53 pregnancy/puerperium (25 with LDA, 12 with low molecular weight heparin and 16 with both), 30 events (9 surgery/immobilisation and 21 pregnancy/puerperium) were non-treated.